Baqsimi Nasal Powder 3mg

Baqsimi is the first and only dry nasal spray for the treatment of severe hypoglycemia in people with diabetes. Originally developed by Locamia Solutions and later acquired and brought to market by Eli Lilly and Company, the brand underwent a significant ownership change in 2023. Eli Lilly sold the global rights for Baqsimi to Amphastar Pharmaceuticals for an upfront payment plus future milestones.

Manufacturing for such specialized medical devices and hormonal treatments often involves complex global supply chains, typically involving facilities in the United States and Europe to ensure stringent pharmaceutical standards. As of 2024 and beyond, Amphastar Pharmaceuticals is the ultimate owner responsible for the production and distribution of this life-saving medication.